Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety

doi:10.4239/wjd.v15.i7.1518

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2193)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-5) series.

Item

Count

PDF

132

HTML

1291

Figures (1-6)

185

Tables (1-5)

184

Sum=1792

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

219

Sum=288

Jul 15, 2024 (publication date) through Feb 27, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Jul 15, 2024; 15(7): 1518-1530
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1518

Full Size Figure Download Figure

Figure 3 Comparison of changes in cardiac function before and after treatment in two groups of patients. A: The changes in left ventricular ejection fraction before and after treatment in both groups; B: The changes in left ventricular end-systolic diameter before and after treatment in both groups; C: The changes in left ventricular end-diastolic diameter before and after treatment in the two groups of patients. ^cP < 0.001. LVEF: Left ventricular ejection fraction; LVEDD: Left ventricular end-diastolic diameter; LVESD: Left ventricular end-systolic diameter.

Citation: Yu PL, Yu Y, Li S, Mu BC, Nan MH, Pang M. Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety. World J Diabetes 2024; 15(7): 1518-1530
URL: https://www.wjgnet.com/1948-9358/full/v15/i7/1518.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i7.1518